Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates

Publisher: La Merie Publishing
Pages: 25
Format: PDF and Online
Product Line:
Competitor Analysis
Product Code: LMCA0144
Release Date: January of 2015

200.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates

The Competitive Intelligence report about Nonalcoholic Steatohepatitis (NASH) - Novel Drug Candidates provides a competitor analysis in the development pipeline of novel therapeutics for treatment of NASH. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Nonalcoholic hepatosteatosis (NASH) is a common, serious chronic liver disease characterized by inflammation and excessive fat accumulation in the liver and may lead to progressive fibrosis, cirrhosis and liver failure. NASH is estimated to affect 10 to 20 percent of people in the developed world. There are currently no approved therapies to treat NASH.

NASH is similar to alcohol-induced steatohepatitis, and is associated with factors that cause an increase in oxidative stress and promote expression of proinflammatory cytokines. NASH is the most common cause of fibrosis and cirrhosis in patients with unexplained increased alanine aminotransferase.

Currently, the diagnosis of hepatic fibrosis is most commonly conducted by a liver biopsy. With magnetic resonance elastography, in use in the United States since 2009 and in Japan since 2012, it has become possible to measure the relative stiffness of liver tissues in a non-invasive manner.

The report provides a compilation of active projects in research and development for treatment of NASH including small molecules, antibodies, peptides and RNAi. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Competitor Analysis: Nonalcoholic Steatohepatitis (NASH) – Novel Drug Candidates

Table of Contents

  • Clinical Stage Drug Candidates for Treatment of NASH
  • Preclinical Stage Drug Candidates for Treatment of NASH

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up